Dear Editor:

Survival for childhood cancer has dramatically improved, particularly for acute lymphoblastic leukemia, reaching over 90% overall survival in industrialized countries \[[@CR1]\]. However, some patients may encounter severe adverse events, limiting this high success rate. ARF is one of the most serious complications and is associated with high mortality if conventional therapy fails \[[@CR2]\]. Escalation to ECMO has rarely been used in patients with malignancy due to its limited success rates and higher risk for infectious and bleeding complications \[[@CR3]--[@CR5]\].

We report on a single centre experience of ECMO on patients with childhood leukemia and ARF. This retrospective study was approved by the local research ethics committee. Nine patients with childhood leukemia received ECMO in induction treatment (8/9 at first remission, 1/9 at second remission) between January 2004 and June 2017. Details on these patients are provided in Table [1](#Tab1){ref-type="table"}. ARF resulted from pulmonary infections (two patients with *Candida albicans*, one patient with *Aspergillus terreus*, four patients with no organisms identified) and pulmonary non-infectious complications (one patient with transfusion-related acute lung injury and one patient with leukemic infiltration). Median duration of mechanical ventilation before ECMO was 3 days (range 0.4--14). The median duration of ECMO support was 14 days (range 2--24). Five (56%) patients survived ECMO und four (44%) survived to hospital discharge. When compared to survivors, non-survivors had a significantly higher vasoactive inotrope score (VIS) at ECMO initiation (85 vs. 11; *p* = 0.032), including two patients requiring veno-arterial cannulation. Time on ECMO support was shorter (5 vs. 15 days; *p* = 0.032) in non-survivors and was stopped because of multiorgan failure (22%), intracranial bleeding (11%) and progressive leukemia (11%). One patient (11%) recovered from hematopoietic stem cell transplantation performed on ECMO, but died two months later of septic shock. Moreover, non-survivors had significantly lower platelet count on ECMO (30 ×  10^3^/μL vs 98 × 10^3^/μL; *p* = 0.041). Eight (89%) patients received chemotherapy in the four weeks prior to and five (56%) were neutropenic at ECMO cannulation. Neutropenic patients did not have higher mortality compared to those without neutropenia (3/5 vs 2/4).Table 1Clinical characteristics and demographics of patients on ECMOClinical characteristicsNDemographicsAllSurvivorsNon-survivors*p*-valueDiagnosisAge (years)14 (1--18)9 (4--16)16 (1--18)0.286 ALL5Weight (kg)47 (7--74)26 (12--50)56 (7--74)0.286 AML3Pre ECMO JMML1pH7.2 (7.0--7.6)7.3 (7.0--7.6)7.2 (7.0--7.4)0.413Reason for ARFLactate (mg/dL)17 (7--68)17 (7--24)17 (8--68)0.556 Fungal infection3pO2/FiO247 (32--67)66 (32--67)44 (34--50)0.286 Pulmonary infection^a^4VIS score45 (5--160)11 (5--45)85 (22--160)0.032 TRALI1Platelet count (×  10^3^/μL)27 (14--214)145 (26--214)27 (14--53)0.111 Leukemic infiltration1Ventilation days3 (0.4--14)4.5 (1--13)2 (0.4--12)0.556Causes of death on ECMODuring ECMO Intracranial hemorrhage1Platelet count (×  10^3^/μL)35 (19--106)98 (22--106)30 (19--48)0.041 Multiorgan failure2Platelets transfusions / day2.2 (0.2--3.8)0.5 (0.2--2.2)3.3 (1.7--4.7)0.111 Leukemic infiltration1VV Cannulation752Outcome on ECMOVA Cannulation202 Survived on ECMO5Major bleeding404 Discharged from hospital4Need for CRRT303 Survived long-term4ECMO Duration (days)14 (2--24)15 (9--24)5 (2--17)0.032^a^no organism detected*ALL* acute lymphoblastic leukemia, *AML* acute myeloid leukemia, *JMML* juvenile myelomonocytic leukemia, *ARF* acute respiratory failure, ^a^no organism detected, *ECMO* extracorporeal membrane oxygenation, *TRALI* transfusion-related acute lung injury, *VIS* vasoactive inotrope score = dose of dopamine (μg/kg/min) + dose of dobutamine (μg/kg/min) + 100 x dose of adrenaline (μg/kg/min) + 100 x dose of noradrenaline (μg/kg/min) + 10 x milrinone dose (μg/kg/min) + 10,000 x dose of vasopressin (U/kg/min), *VV* veno-venous, *VA* veno-arterial, *CRRT* continuous renal replacement therapy

All four survivors are in complete oncologic remission at a median follow-up of 8.4 years (range 1.8--13.1), are restored to full health, and are all engaged to full-time study or work. Our data is limited by a small sample size and by its retrospective analysis. Nevertheless, it indicates that ECMO provides an effective rescue therapy in childhood leukemic patients with ARF.

ARF

:   Acute respiratory failure

ECMO

:   Extracorporeal membrane oxygenation

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.
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